Systolic myocardial mechanics in patients with Anderson-Fabry disease with and without left ventricular hypertrophy and in comparison to nonobstructive hypertrophic cardiomyopathy

Echocardiography

Volumn 29, Issue 7, 2012, Pages 810-817

  Gruner, Christiane ^a   Verocai, Flavia ^a   Carasso, Shemy ^b   Vannan, Mani A ^c   Jamorski, Michael ^a   Clarke, Joe T R ^d   Care, Melanie ^e   Iwanochko, Robert M ^a   Rakowski, Harry ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Anderson Fabry disease; hypertrophic cardiomyopathy; speckle tracking; strain

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; FOLLOW UP; HEART CONTRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART SIZE; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMAGE QUALITY; MALE; MECHANICS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

CARDIOMYOPATHY, HYPERTROPHIC; FABRY DISEASE; FEMALE; HEART FAILURE, SYSTOLIC; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84865087957     PISSN: 07422822     EISSN: 15408175     Source Type: Journal    
DOI: 10.1111/j.1540-8175.2012.01704.x     Document Type: Article

References (31)

1. Desnick RJ, Brady R, Barranger J, et al,: Fabry disease, an under-recognized multisystemic disorder: Expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003; 138: 338-346.
2. Mehta A, Beck M, Eyskens F, et al,: Fabry disease: A review of current management strategies. QJM 2010; 103: 641-659.
3. Chimenti C, Morgante E, Tanzilli G, et al,: Angina in Fabry disease reflects coronary small vessel disease. Circ Heart Fail 2008; 1: 161-169.
4. Takenaka T, Teraguchi H, Yoshida A, et al,: Terminal stage cardiac findings in patients with cardiac Fabry disease: An electrocardiographic, echocardiographic, and autopsy study. J Cardiol 2008; 51: 50-59.
5. Wu JC, Ho CY, Skali H, et al,: Cardiovascular manifestations of Fabry disease: Relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity. Eur Heart J 2010; 31: 1088-1097.
6. Monserrat L, Gimeno-Blanes JR, Marin F, et al,: Prevalence of Fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2007; 50: 2399-2403.
7. Elliott P, Baker R, Pasquale F, et al,: Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: The European Anderson-Fabry Disease Survey. Heart 2011; 97: 1957-1960.
8. Patel MR, Cecchi F, Cizmarik M, et al,: Cardiovascular events in patients with Fabry disease natural history data from the Fabry registry. J Am Coll Cardiol 2011; 57: 1093-1099.
9. Mehta A, Beck M, Elliott P, et al,: Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: An analysis of registry data. Lancet 2009; 374: 1986-1996.
10. Weidemann F, Niemann M, Breunig F, et al,: Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: Evidence for a better outcome with early treatment. Circulation 2009; 119: 524-529.
11. Hughes DA, Elliott PM, Shah J, et al,: Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: A randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 2008; 94: 153-158.
12. Linhart A, Elliott PM,: The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart 2007; 93: 528-535.
13. Varnava AM, Elliott PM, Sharma S, et al,: Hypertrophic cardiomyopathy: The interrelation of disarray, fibrosis, and small vessel disease. Heart 2000; 84: 476-482.
14. Maron MS, Appelbaum E, Harrigan CJ, et al,: Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ Heart Fail 2008; 1: 184-191.
15. Pieroni M, Chimenti C, Ricci R, et al,: Early detection of Fabry cardiomyopathy by tissue Doppler imaging. Circulation 2003; 107: 1978-1984.
16. Zamorano J, Serra V, Perez de Isla L, et al,: Usefulness of tissue Doppler on early detection of cardiac disease in Fabry patients and potential role of enzyme replacement therapy (ERT) for avoiding progression of disease. Eur J Echocardiogr 2011; 12: 671-677.
17. Castro PL, Greenberg NL, Garcia MJ, Thomas JD,: Potential pitfalls of strain rate imaging: Angle dependency. Biomed Sci Instrum 2000; 36: 197-202.
18. Biaggi P, Carasso S, Garceau P, et al,: Comparison of two different speckle tracking software systems: Does the method matter? Echocardiography 2011; 28: 539-547.
19. Gersh BJ, Maron BJ, Bonow RO, et al,: 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011; 58 (25): e212-e260.
20. Lang RM, Bierig M, Devereux RB, et al,: Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18: 1440-1463.
21. Quinones MA, Otto CM, Stoddard M, et al,: Recommendations for quantification of Doppler echocardiography: A report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr 2002; 15: 167-184.
22. Devereux RB, Alonso DR, Lutas EM, et al,: Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol 1986; 57: 450-458.
23. Mehta A, Clarke JT, Giugliani R, et al,: Natural course of Fabry disease: Changing pattern of causes of death in FOS-Fabry Outcome Survey. J Med Genet 2009; 46: 548-552.
24. Toro R, Perez-Isla L, Doxastaquis G, et al,: Clinical usefulness of tissue Doppler imaging in predicting preclinical Fabry cardiomyopathy. Int J Cardiol 2009; 132: 38-44.
25. Carasso S, Yang H, Woo A, et al,: Systolic myocardial mechanics in hypertrophic cardiomyopathy: Novel concepts and implications for clinical status. J Am Soc Echocardiogr 2008; 21: 675-683.
26. Garceau P, Nguyen ET, Carasso S, et al,: Quantification of myocardial iron deposition by two-dimensional speckle tracking in patients with beta-thalassaemia major and Blackfan-Diamond anaemia. Heart 2011; 97: 388-393.
27. Abozguia K, Nallur-Shivu G, Phan TT, et al,: Left ventricular strain and untwist in hypertrophic cardiomyopathy: Relation to exercise capacity. Am Heart J 2010; 159: 825-832.
28. Sun JP, Stewart WJ, Yang XS, et al,: Differentiation of hypertrophic cardiomyopathy and cardiac amyloidosis from other causes of ventricular wall thickening by two-dimensional strain imaging echocardiography. Am J Cardiol 2009; 103: 411-415.
29. Carasso S, Cohen O, Mutlak D, et al,: Relation of myocardial mechanics in severe aortic stenosis to left ventricular ejection fraction and response to aortic valve replacement. Am J Cardiol 2011; 107: 1052-1057.
30. De Cobelli F, Esposito A, Belloni E, et al,: Delayed-enhanced cardiac MRI for differentiation of Fabry's disease from symmetric hypertrophic cardiomyopathy. Am J Roentgenol 2009; 192: W97-102.
31. Chimenti C, Hamdani N, Boontje NM, et al,: Myofilament degradation and dysfunction of human cardiomyocytes in Fabry disease. Am J Pathol 2008; 172: 1482-1490.